Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...
Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...
By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...
Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, ...
A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) ...
Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in first-line diffuse large b-cell lymphoma (DLBCL) will be ...
A 10-year follow-up confirms the potential role of doxycycline in treating conjunctival lymphoma associated with urogenital chlamydia.
Could glandular fever lead to brain lymphoma? Specialists Dr Adolfo de la Fuente and Dr Agustín Penedo explain the ...
Researchers at the Josep Carreras Leukaemia Research Institute (IJC) discover that a single molecular switch, HDAC7, controls ...
Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026SOUTH SAN FRANCISCO, Calif., April ...
The immune system is designed to protect us against viruses and bacteria. In autoimmune diseases, however, the immune system instead attacks the body's own cells. Conditions such as systemic lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results